CS

Charandeep Singh

Active Director Director DIN 08306582
DIN 08306582 First appointment Dec 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2018
Shareholding value •••• Premium profile

About Charandeep Singh

Data last updated:

Charandeep Singh is a Director at Foxcem Pharmaceuticals Limited (since 2018). The company operates in Pharma. Foxcem Pharmaceuticals Limited reported revenue of ₹8.3 Lakh (FY 2021).

DIN 08306582
Primary Designation Director
Industry Pharma
First Appointment 17 Dec 2018
Oldest Company Age 7 yrs
Largest company Foxcem Pharmaceuticals Limited · ₹8.3 Lakh (FY 2021)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Foxcem Pharmaceuticals Limited U52609HP2018PLC007272
Director17 Dec 20182018₹8.3 Lakh (FY 2021)Active

Board colleagues of Charandeep Singh

Directorship timeline

Open interactive timeline →
Foxcem Pharmaceuticals Limited
Premium access

Shareholding and investment profile for Charandeep Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Charandeep Singh

Charandeep Singh currently holds 1 directorship: Foxcem Pharmaceuticals Limited (Director, since 17 Dec 2018, revenue ₹8.3 Lakh (FY 2021)).

Charandeep Singh was first appointed on 17 Dec 2018 as Director at Foxcem Pharmaceuticals Limited.

The current boards of Charandeep Singh's companies include Amandeep Singh (Foxcem Pharmaceuticals Limited), Parmeet Kaur (Foxcem Pharmaceuticals Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available